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Introduction
Gefitinib (Iressa®; AstraZeneca Pharmaceuticals,
Wilmington, DE, USA) is an orally active, selective
epidermal growth factor receptor-tyrosine kinase
inhibitor (EGFR-TKI) that is an effective treatment
for advanced non-small-cell lung cancer (NSCLC).1,2
Generally, gefitinib is well tolerated, and most drug-
related adverse events are mild and manageable.
However, gefitinib-related interstitial pneumonia has
been reported, and the incidence seems to differ
between Japan and Western countries.3,4
From March 2002 to May 2003, we prospectively
enrolled 76 patients with advanced NSCLC in a
single-institute study in Taiwan.5 Gefitinib was admin-
istered orally at a fixed daily dosage of 250 mg, with-
out concomitant cytotoxic agents or radiotherapy.
Patients were eligible for study inclusion if they had
failed previous systemic chemotherapy, or had poor
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performance status during cytotoxic therapy. Sixty-
nine patients were evaluated for drug-related toxicity.
Here, we present 4 cases in which patients developed
interstitial pneumonia during gefitinib treatment:
1 case occurred during the second week; 2 in the
second month; and 1 in the fourth month.
Case Reports
Case 1
An 80-year-old man was diagnosed, in June 2002,
with adenocarcinoma in the left lower lung lobe
(Figure 1A). He received single-agent, systemic
chemotherapy with gemcitabine (4 courses).
Chemotherapy was stopped because of pulmonary
tuberculosis, which was considered to be related to
treatment-induced immunosuppression. The patient
then received gefitinib, and his disease was stable at
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the response evaluation in the eighth week; however,
ground-glass opacities were noted incidentally in
both lower lung fields (Figure 1B). No evidence of
infection, fluid overload, or disease progression
was noted clinically. Laboratory tests revealed a nor-
mal blood cell count, and all serologic tests and
microbiologic cultures were negative. Because of
suspected drug-related interstitial pneumonia,
gefitinib was discontinued, and methylprednisolone
was prescribed. One week later, a chest computed
tomography (CT) scan showed dramatic improvement
(Figure 1C).
Case 2
In February 2003, a 70-year-old man with NSCLC
presented with multiple lung and bone metastases
(Figure 2A). In March 2003, the patient underwent
surgery for stabilization of the lumbar spine, and
palliative radiotherapy of the lower thoracic spine;
because of poor performance status, he received
gefitinib as first-line systemic therapy. Progressive
shortness of breath, dyspnea on exertion and mild
cough were noted after 8 weeks’ treatment when
the patient returned for an evaluation of treatment
response. A chest CT scan showed a partial response
of the tumor; however, diffuse, ground-glass
opacities were noted in both lungs (Figure 2B).
There were no clinical signs of infection and fluid
overload, and radiation pneumonitis was not favored
as the diagnosis since radiographic changes that
usually manifest 2–3 months after radiation therapy
were absent. Because of suspected gefitinib-induced
interstitial pneumonitis, gefitinib was discontinued
and glucocorticosteroid therapy was given. Clinical
symptoms improved, and a chest CT scan showed
remarkable regression of interstitial pneumonia,
with residual fibrotic change in the right lower lung
lobe (Figure 2C).
Case 3
A 69-year-old woman presented with NSCLC in the
left lower lung lobe in November 2001. She had
radiotherapy as her initial treatment; however, tumor
progression and lung metastases were noted in February
2002. The patient then received systemic chemotherapy
with vinorelbine and cisplatin (6 courses), and the
maximal response was stable disease. Two months
later, disease progression was noted; the patient
then took gefitinib as second-line therapy. However,
aggravated dyspnea and cough were noted after 2
weeks of gefitinib treatment. No evidence of infec-
tion, fluid overload or disease progression was noted
clinically. Laboratory tests revealed a normal blood
Figure 2. (A) Multiple pulmonary metastases were noted in both
lung fields at initial presentation in a patient with non-small-cell
lung cancer. (B) Diffuse, ground-glass opacities and interlobular
septal thickening in the superior basal segment of the right lower
lung lobe were noted after 8 weeks of gefitinib treatment, despite
a remarkable tumor response. (C) Remarkable regression of
interstitial pneumonia, with residual fibrotic change in the right
lower lung lobe, was noted after discontinuing gefitinib and
starting methylprednisolone.
Figure 1. A case of non-small-cell lung cancer: (A) tumor infiltra-
tion was noted in the left lower lung lobe at initial presentation;
(B) ground-glass opacities were found incidentally in both lower-
lung fields at the response evaluation; and (C) the lesion re-
solved dramatically 1 week after discontinuing gefitinib and
starting methylprednisolone.
cell count, and all serologic tests and microbiologic
cultures were negative. A chest radiograph showed a
ground-glass opacity and consolidation in the right
upper lung lobe. Gefitinib was discontinued immedi-
ately, and methylprednisolone was prescribed. A chest
radiograph performed 6 weeks later showed prompt
resolution of the lesion, despite progression of the
main tumor.
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Case 4
A 64-year-old man was diagnosed with squamous
cell carcinoma of the lung in July 2002. The clinical
staging was T3N3M1 at initial presentation. Because of
poor performance status, the patient received gefitinib
as first-line therapy. The tumor was stable, but pro-
gressive shortness of breath and cough were noted
after 4 months’ gefitinib treatment. A chest CT scan
showed a ground-glass opacity in the left lower lung
lobe. Microbiologic tests of sputum and blood were all
negative, and there was no evidence of fluid overload.
Laboratory tests revealed a normal blood cell count,
and a normal differential count of white blood cells.
Gefitinib-related interstitial pneumonia was highly
suspected. Gefitinib was withdrawn and methyl-
prednisolone was prescribed. Clinical symptoms
resolved promptly, and a chest CT scan performed 3
months later showed complete resolution of the lesion.
Discussion
Gefitinib is an orally active, selective EGFR-TKI
with anti-tumor activity against several kinds of
neoplasm. Two large phase II trials, the Iressa®
Dose Evaluation for Advanced Lung Cancer
(IDEAL)-1 and IDEAL-2, showed that gefitinib
was effective in NSCLC patients who had failed
previous platinum-based chemotherapy,1,2 and
gefitinib, as a targeted therapy, has a better toxicity
profile than conventional cytotoxic chemotherapy.
In fact, in the IDEAL-1 and IDEAL-2 trials, most
drug-related adverse events were mild to moder-
ate, namely skin toxicity and gastrointestinal distur-
bances, and were manageable.1,2
Based on these data, gefitinib was first approved
in Japan in July 2002. However, some cases of fatal
gefitinib-related interstitial pneumonia were noted
after the drug was marketed. Inoue et al3 first formally
reported, in the English literature, that 4 of 18
gefitinib-treated patients developed severe acute
interstitial pneumonia. The authors also cited that,
according to an official notice by the Japanese Ministry
of Health, Labour, and Welfare, 1.7% of 175,000
patients had suspected interstitial pneumonia during
gefitinib therapy. Thus, the US Food and Drug
Administration delayed gefitinib approval until May
2003, even though they claimed that the incidence of
gefitinib-induced interstitial pneumonia was only
about 0.3% in the US expanded access program.4
A retrospective survey conducted by the West Japan
Thoracic Oncology Group, and performed indepen-
dently of AstraZeneca Pharmaceuticals and regula-
tory authorities, revealed a 1983 incidence of 4.6%
for interstitial pneumonia in NSCLC patients treated
with gefitinib; 30 patients (1.5%) had died from this
gefitinib-related complication.6
A definitive diagnosis of drug-induced interstitial
pneumonia is difficult; moreover, the mechanism of
gefitinib-induced interstitial pneumonia is unclear.
Since the histologic findings of drug-induced intersti-
tial pneumonia are usually non-specific, and as it is
not feasible to risk re-injury through re-challenge with
gefitinib in most patients with advanced NSCLC who
have had such pneumonia, the diagnosis of interstitial
pneumonia in our series was based on the following
factors: clinical presentation; characteristic findings
on CT scan; exclusion of infectious disease and fluid
overload; and the prompt resolution of symptoms
and imaging findings after gefitinib discontinuation.
Gefitinib-related interstitial pneumonia was clinically
diagnosed in 4 patients in our series. The time from
starting gefitinib to the occurrence of interstitial
pneumonia ranged from 2 weeks to 4 months. All
patients were treated by gefitinib withdrawal and the
concomitant administration of methylprednisolone
16 mg/day. The glucocorticosteroid dosage was
tapered progressively according to clinical status, all
patients recovered from interstitial pneumonia, and
no related deaths were noted.
Interestingly, the occurrence of interstitial pneu-
monia was irrespective of tumor response. When in-
terstitial pneumonia occurred, 1 patient had a partial
response, 2 had stable disease, and 1 had progres-
sive disease. The most common adverse events in our
series5 were similar to those reported previously. How-
ever, the incidence of interstitial pneumonia (5.8%) was
greater than that in reports from Western countries,
but close to that reported in Japan, thus suggesting
ethnic differences that warrant further investigation.
Generally, gefitinib is well tolerated, and most
drug-related adverse events are mild to moderate and
manageable. Nonetheless, our observations suggest
that gefitinib-related interstitial pneumonia is not
rare, at least in certain races and regions. Mortality
from such pneumonia in gefitinib-treated patients
with NSCLC can be prevented by early recognition
of new-onset respiratory symptoms and prompt ra-
diographic examination, and by stopping gefitinib
but starting glucocorticosteroid therapy whenever
pulmonary toxicity is highly suspected.
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